EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access

S-Adenosylmethionine (SAMe) for Neuropsychiatric Disorders

Anup Sharma, Patricia Gerbarg, Teodoro Bottiglieri, Lila Massoumi, Linda L Carpenter, Helen Lavretsky, Philip R Muskin, Richard P Brown, David Mischoulon, as Work Group of the American Psychiatric Association Council on Research

The Journal of Clinical Psychiatry · 28.06.2017 · 78 (06) · e656-e667

DOI: 10.4088/jcp.16r11113 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift The Journal of Clinical Psychiatry, erschienen am 28.06.2017. Verfasst von Anup Sharma und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry, University of Pennsylvania School of Medicine, 10th Floor Gates Bldg, 3400 Spruce St, Philadelphia, PA 19104. anup@mail.med…. Die Arbeit wurde bisher 152-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIMH NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: A systematic review on S-adenosylmethionine (SAMe) for treatment of neuropsychiatric conditions and comorbid medical conditions. DATA SOURCES: Searches were conducted in PubMed, EMBASE, PsycINFO, Cochrane Library, CINAHL, and Google Scholar databases between July 15, 2015, and September 28, 2016, by combining search terms for SAMe (s-adenosyl methionine or s-adenosyl-l-methionine) with terms for relevant disease states (major depressive disorder, MDD, depression, perinatal depression, human immunodeficiency virus, HIV, Parkinson's, Alzheimer's, dementia, anxiety, schizophrenia, psychotic, 22q11.2, substance abuse, fibromyalgia, osteoarthritis, hepatitis, or cirrhosis). Additional studies were identified from prior literature. Ongoing clinical trials were identified through clinical trial registries. STUDY SELECTION: Of the 174 records retrieved, 21 were excluded, as they were not original investigations. An additional 21 records were excluded for falling outside the scope of this review. Of the 132 studies included in this review, 115 were clinical trials and 17 were preclinical studies. DATA EXTRACTION: A wide range of studies was included in this review to capture information that would be of interest to psychiatrists in clinical practice. RESULTS: This review of SAMe in the treatment of major depressive disorder found promising but limited evidence of efficacy and safety to support its use as a monotherapy and as an augmentation for other antidepressants. Additionally, preliminary evidence suggests that SAMe may ameliorate symptoms in certain neurocognitive, substance use, and psychotic disorders and comorbid medical conditions. CONCLUSIONS: S-adenosylmethionine holds promise as a treatment for multiple neuropsychiatric conditions, but the body of evidence has limitations. The encouraging findings support further study of SAMe in both psychiatric and comorbid medical illnesses.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HumansMental DisordersNervous System DiseasesS-Adenosylmethionine

Substanzen

S-Adenosylmethionine

Autor:innen und Institutionen

  • Department of Psychiatry, University of Pennsylvania School of Medicine, 10th Floor Gates Bldg, 3400 Spruce St, Philadelphia, PA 19104. anup@mail.med.upenn.edu.
  • Department of Psychiatry, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Department of Psychiatry, New York Medical College, Vahalla, New York, USA.
  • Institute of Metabolic Disease, Baylor Research Institute, Dallas, Texas, USA.
  • Department of Psychiatry, Michigan State University, East Lansing, Michigan, USA.
  • Butler Hospital, Brown Department of Psychiatry and Human Behavior, Providence, Rhode Island, USA.

Förderung

  • NIMH NIH HHS

Zitieren

APA

Sharma, A., Gerbarg, P., Bottiglieri, T., Massoumi, L., Carpenter, L. L., Lavretsky, H., Muskin, P. R., Brown, R. P., Mischoulon, D., & as Work Group of the American Psychiatric Association Council on Research (2017). S-Adenosylmethionine (SAMe) for Neuropsychiatric Disorders. The Journal of Clinical Psychiatry, 78(06), e656-e667. https://doi.org/10.4088/jcp.16r11113

Vancouver

Sharma A, Gerbarg P, Bottiglieri T, Massoumi L, Carpenter LL, Lavretsky H, et al. S-Adenosylmethionine (SAMe) for Neuropsychiatric Disorders. The Journal of Clinical Psychiatry. 2017;78(06):e656-e667. doi:10.4088/jcp.16r11113

BibTeX
@article{Sharma2017,
  author = {Sharma, Anup and Gerbarg, Patricia and Bottiglieri, Teodoro and Massoumi, Lila and Carpenter, Linda L and Lavretsky, Helen and Muskin, Philip R and Brown, Richard P and Mischoulon, David and as Work Group of the American Psychiatric Association Council on Research, as Work Group of the American Psychiatric Association Council on Research},
  title = {S-Adenosylmethionine (SAMe) for Neuropsychiatric Disorders},
  journal = {The Journal of Clinical Psychiatry},
  year = {2017},
  volume = {78},
  number = {06},
  pages = {e656--e667},
  doi = {10.4088/jcp.16r11113}
}
Kostenlos starten →